A Forward Look, The Year Ahead - Research Report on Questcor Pharmaceuticals Inc., Actavis Inc., American International Group

 A Forward Look, The Year Ahead - Research Report on Questcor Pharmaceuticals
Inc., Actavis Inc., American International Group Inc., ACE Limited and Flowers
                                 Foods, Inc.

PR Newswire

NEW YORK, March 15, 2013

NEW YORK, March 15, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Questcor
Pharmaceuticals Inc. (NASDAQ:QCOR), Actavis Inc. (NYSE:ACT), American
International Group Inc. (NYSE:AIG), ACE Limited (NYSE:ACE) and Flowers Foods,
Inc. (NYSE:FLO). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Questcor Pharmaceuticals Inc. Research Report

Questcor Pharmaceuticals, Inc. has recently posted a huge 212% increase to
$160.5 million for the fourth quarter net sales, and a 234% increase to $509.3
million for the full year. The company's GAAP earnings for the latest quarter
were $1.03 per diluted common share, compared to 48 cents per diluted common
share compared to the same year-ago quarter. The company also increased its
quarterly dividend by 25% to 25 cents per share. "Net sales, net income and
cash flow from operations grew sharply in the fourth quarter compared to the
prior-year period," said Don M. Bailey, President and CEO of Questcor. This
growth was brought about by the expansion of the prescription of H.P. Acthar®
Gel, a repository hormone injection designed to prolong the release of
medication. With the launch of commercial activities focusing the use of the
drug on the treatment of rheumatology-related conditions, the increased
prescription for the treatment of nephrotic syndrome by nephrologists as well
as the prescriptions by neurologists for the treatment of MS relapses and
infantile spasms, Acthar proved to be the significant factor in the company's
recent growth. During the latest quarter, 6,330 vials of Acthar were shipped
while a total of 20,741 vials were shipped for the full year. "We continue to
invest in the future of both Acthar and our overall business capabilities,"
said Bailey. "In addition to the rapid expansion of our R&D investment, we
have also substantially expanded our sales force, our reimbursement and
compliance teams, and our manufacturing capabilities." January this year,
Questcor completed the acquisition of Bio Vectra Inc., a supplier of contract
manufacturing services and the company's manufacturing partner for the active
ingredient used in Acthar. The Full Research Report on Questcor
Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:


Actavis Inc. Research Report

Actavis Inc. posted significant increases in earnings. The New Jersey-based
pharmaceutical company reported a 13% increase to $1.75 billion for the latest
quarter and a full-year revenue increase of 29% to $5.91 billion. Actavis also
announced a diluted earnings per share of $1.59. Formerly Watson
Pharmaceuticals, Inc., the company underwent major re-branding upon the
acquisition of the Actavis Group. "With the close of the Actavis acquisition
and combination of our two companies, under our new global name, Actavis,
Inc., we are beginning 2013 on a solid commercial and financial foundation,
well-positioned for sustainable long-term growth," said Actavis President and
CEO Paul Bisaro said. The company launched 1,000 generic products and filed
more than 1,500 applications globally. In January 2013, Actavis the
acquisition of Uteron Pharma SA begins the expansion and development of the
company's Women's Health portfolio program. Actavis has also recently received
approval from the FDA for its ANDA for Buprenorphine HCl and Naloxone HCl
Dihydrate SL Tablets, 2 mg/0.5 mg and 8 mg/2 mg, the generic equivalent to
Reckitt Benckiser Healthcare's Suboxone®. The company expects a total net
revenue of $8.1 billion for the coming year. "We are focused on repaying our
debt and maintaining a strong financial foundation to support strategic growth
initiatives within our global businesses," Bisaro concluded. The Full Research
Report on Actavis Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:


American International Group Inc. Research Report

Analysts view AIG's position in the market as stable, with ability acquire and
retain clients through its global presence, and diverse product offerings and
innovation. The company has just recently settled an agreement for an
exclusive distribution relationship with HSBC in Turkey and France. As the
exclusive provider of non-life insurance providers to the customers of HSBC
Group, AIG expects to pay an approximately $55 million-worth of distribution
access. The 10-year bancassurance agreement is geared towards the expansion of
the distribution arrangement and operations platforms with HSBC in Turkey as
well as the acquisition of HSBC's non-life subsidiary in France, HSBC IARD.
Aside from overseas expansion, AIG is also looking to securing its share in
the online application market with the development of the CyberEdge Mobile App
for the iPad to address the rising concern about cyber threats and other
business risks. As part of the company's CyberEdge Insurance Solution, AIG has
also launched other tools such as third-party protection hardware AutoShun and
risk management web portal CyberEdge RiskTool. The Full Research Report on
American International Group Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:


ACE Limited Research Report

Zurich-based ACE, meanwhile, has announced the start of the company's energy
risks underwriting through Syndicate 2488 at Lloyd's of London. Expecting to
complement ACE's existing energy portfolio, ACE will write offshore risks on a
global perspective, while also writing onshore risks on a global basis
excluding North America. This move is geared towards extending the company's
presence in the energy sector, especially in the oil and gas markets. ACE also
targets Continental Europe's food and drink industry with the recent launch of
a collaboration with red24assist. Partnering with the said global specialist
in risk assessment, the insurance company aims to provide businesses with
revenues of up to €1 billion with services such as pre-event risk management
advice and support as well as protection from costly recall incidents. ACE
reports that with the risk landscape of Europe's food and drink industry, the
solutions provided by the company in collaboration with red24assist will help
ensure access to risk management support for the clients. The Full Research
ACE Limited - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:


Flowers Foods, Inc. Research Report

Flowers Foods, Inc., a major producer and distributor of baked goods based in
Thomasville, Georgia has announced a 17% increase in sales for the latest
quarter, amounting to $749.4 million, and a full-year growth in sales of 9.8%
to $3.05 billion. With volume increase of 10.3% for the quarter and 2.1% for
the full year, the company posted diluted EPS of $1.03. Becoming the
best-selling bread brand, the company's Nature's Own reached approximately
$974 million in annual retail sales while 6.4% of the total sales growth is
attributed to acquisitions made over the year. This month, the company has
completed the acquisition of the licenses of Sara Lee and Earthgrains brands
for sliced breads, buns, and rolls in California. As these products are
distributed immediately in Southern California and further northward, the
company expects to bolster brand presence in the state, augmenting the brand's
reach by about 14.5 million people. "With pending acquisitions and market
expansions currently underway, we expect to surpass our 2016 goal of reaching
75 percent of the U.S. population with our fresh baked foods three years ahead
of schedule," Flowers President and CEO Allen L. Shiver noted. "Even so, we
will have significant growth opportunities in our new markets and in our core
territories for years to come and I am confident on our team's ability to
achieve our long-term growth objectives," he concluded. The Full Research
Report on Flowers Foods, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:


Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Patricia Byers
Email: press@Investors-Alliance.com
Main: +1-480-745-7826

SOURCE Investors-Alliance
Press spacebar to pause and continue. Press esc to stop.